Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
Study Details
Study Description
Brief Summary
Currently, no data exists regarding the safety and tolerability of a combination regimen utilizing weekly topotecan in combination with pemetrexed. Although both drugs are associated with myelosuppression, it is hoped that the utilization of the weekly topotecan dosing schedule will allow the drugs to be easily combined. This phase I trial will evaluate the safety and tolerability of weekly topotecan in combination with pemetrexed in patients with advanced solid tumors.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
Three patients will be accrued at each of 5 dose levels. Dose escalation will only proceed if none of the additional 3 patients experience DLT. The highest dose level that generates DLT in 0/3 or 1/6 patients will be the maximum tolerated dose (MTD) or the doses recommended for subsequent studies. A total of 10 patients will be treated at the MTD to further assess the toxicity of the dosing regimen and its suitability for use in subsequent trials. Patients may continue to receive treatment until unacceptable toxicity or disease progression is encountered. Treatment cycles will be repeated every 21 days. The protocol is also designed to enroll an additional 10 patients at the maximum tolerated dose to increase the confidence in the safety and suitability of the doses that are chosen for subsequent studies.
-
Topotecan Day 1 and 8
-
Pemetrexed Day 1
Study Design
Outcome Measures
Primary Outcome Measures
- maximum tolerated doses of drugs in combination []
- overall toxicity of drug combination []
- preliminary antitumor activity of drug combination []
- impact of pemetrexed on topotecan pharmacokinetics []
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically proven advanced solid tumors
-
Measurable or evaluable disease
-
Age ≥ 18 years
-
Karnofsky performance status ≥ 80% (ECOG 0 or 1)
-
Adequate liver, bone marrow and kidney function
Exclusion Criteria:
-
More than 3 prior chemotherapy regimens in the metastatic setting
-
Prior treatment with topotecan or pemetrexed
-
Clinically significant third space fluid present at the time of treatment
-
Unable to interrupt aspirin, other non-steroidal anti-inflammatory drugs
-
Inability to take steroid premedications or vitamin supplementation
-
The presence of active brain metastases
-
Prior radiotherapy within 4 weeks prior to the first day of treatment
-
Prior surgery within 3 weeks prior to the first day of treatment
-
Prior chemotherapy within 3 weeks prior to the first day of treatment
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Tennessee Oncology, PLLC | Nashville | Tennessee | United States | 37023 |
Sponsors and Collaborators
- SCRI Development Innovations, LLC
- GlaxoSmithKline
- Eli Lilly and Company
Investigators
- Principal Investigator: Howard Burris, MD, SCRI Development Innovations, LLC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SCRI REFMAL 72
- 105114
- H3E-US-I013 LILLY